CLINICAL_TRIALS
trial_result
· 2023-07-28
Clinical Trial Update: AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines [Phase 2]
Summary
Phase 2 dose-ranging trial of AGN-151586 for treatment of glabellar lines has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Allergan | Conditions: Glabellar Lines | Phase 2 | Status: COMPLETED | Results posted: 2023-07-28